2.11
Nkarta Inc stock is traded at $2.11, with a volume of 455.99K.
It is down -4.09% in the last 24 hours and up +47.55% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.20
Open:
$2.15
24h Volume:
455.99K
Relative Volume:
0.33
Market Cap:
$131.27M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.8792
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
+16.57%
1M Performance:
+47.55%
6M Performance:
-36.64%
1Y Performance:
-69.06%
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NKTX
Nkarta Inc
|
2.11 | 131.27M | 0 | -117.50M | -114.31M | -2.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Jul-28-22 | Initiated | Needham | Buy |
Jul-18-22 | Initiated | SVB Leerink | Outperform |
Mar-11-22 | Initiated | Raymond James | Outperform |
Mar-08-22 | Initiated | H.C. Wainwright | Buy |
Jan-06-22 | Initiated | William Blair | Outperform |
Nov-18-21 | Initiated | SMBC Nikko | Outperform |
Jul-16-21 | Initiated | Oppenheimer | Outperform |
Aug-04-20 | Initiated | Cowen | Outperform |
Aug-04-20 | Initiated | Evercore ISI | Outperform |
Aug-04-20 | Initiated | Mizuho | Buy |
Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Technical analysis of Nkarta Inc (NKTX) stock chart patterns - uspostnews.com
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 2.18 - DWinneX
Insider Sale Alert: Nkarta Inc [NKTX] – Is it Time to sell? - knoxdaily.com
A Tale of Resilience: Nkarta Inc Amid Stock Market Turbulence - investchronicle.com
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Nkarta (NKTX) Upgraded to Buy: Here's Why - NewsBreak: Local News & Alerts
Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com
American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
CAR NK Expert With 25-Year Track Record Strengthens Senti Bio's Scientific Leadership - Stock Titan
Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
Hager Alicia J. | Chief Legal Officer |
Jul 16 '24 |
Sale |
8.00 |
3,396 |
27,168 |
103,819 |
Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):